Results 41 to 50 of about 30,645 (194)
To describe the Hepatitis B e antigen(HBeAg) seroconversion related mutation profiles of the basal core promoter(BCP)/precore regions in e antigen seroconverted child patients, a cohort of 245 child patients with CHB and a control patients group of 92 ...
Yong Huang +7 more
doaj +1 more source
Background/AimsDespite the potent suppression of the hepatitis B virus with modern antiviral agents, only a minority of HBeAg-positive patients achieve hepatitis B e antigen seroconversion.
Chung-Il Wi +4 more
doaj +1 more source
This perspective outlines China's contributions toward functional‐cure‐oriented antiviral therapies for chronic hepatitis B, summarizing key clinical data on bepirovirsen and domestic drug pipelines with balanced coverage of both promising and disappointing trial results.
Dandan Weng, Zhujun Cao, Qing Xie
wiley +1 more source
Forest plot for HBeAg seroconversion rates 48 weeks post therapy.
Forest plot for HBeAg seroconversion rates 48 weeks post therapy.
Chi Zhang (9857) +6 more
core +1 more source
HBeAg levels at week 24 predict response to 8 years of tenofovir in HBeAg-positive chronic hepatitis B patients [PDF]
BACKGROUND: Hepatitis B e antigen (HBeAg) seroconversion is a treatment endpoint for HBeAg-positive CHB, and a necessary precursor to HBsAg loss. Biomarkers that predict serological outcomes would be useful.
Yuen, L +16 more
core +1 more source
Aim: This study developed and validated a non-invasive scoring model to predict 1-year hepatitis B e antigen (HBeAg) seroconversion in response to nucleos(t)ide analog (NA) treatment in NA-naïve patients with HBeAg-positive chronic hepatitis B (CHB ...
Mingfan Geng +9 more
doaj +1 more source
Disease Progression Mathematical Modeling With a Case Study on Hepatitis B Virus Infection
ABSTRACT Chronic Hepatitis B presents a significant health and socioeconomic burden. The risk of hepatocellular carcinoma remains elevated although treatments are available. Achieving an optimal treatment regimen necessitates a deep comprehension of the dynamic relationship between the virus and its host across disease states.
Clémence Boivin‐Champeaux +6 more
wiley +1 more source
Forest plot for HBeAg seroconversion rates 24 weeks post therapy.
Forest plot for HBeAg seroconversion rates 24 weeks post therapy.
Chi Zhang (9857) +6 more
core +1 more source
The clinical significance of the coexistence of hepatitis B e antigen (HBeAg) and antibodies against HBeAg (anti-HBe) in patients with chronic hepatitis B (CHB) remains unclear.
Ruifei Xue +14 more
doaj +1 more source
Background Adefovir Dipivoxil (ADV) is an important agent to suppress hepatitis B virus (HBV) replication with suboptimal effect on virological and serological response.
Zhang Jing +5 more
doaj +1 more source

